Fly News Breaks for December 17, 2018
FOLD
Dec 17, 2018 | 16:20 EDT
Guggenheim analyst Whitney Ijem started Amicus Therapeutics with a Buy rating and $18 price target. The analyst thinks Amicus shares are well positioned headed into 2019 given the ongoing Galafold launch and the company's "robust pipeline of new gene therapy assets that will produce several updates throughout the year."
News For FOLD From the Last 2 Days
There are no results for your query FOLD